CDK2-IN-4

• CAT Number: I019049
• CAS Number: 2079895-42-2
• Molecular Formula: C₂₃H₁₈N₆O₂S
• Molecular Weight: 442.49
• Purity: ≥95%
• Target: CDK
• Storage: Room Temperature
• IUPAC Name: 4-[[6-(3-phenylphenyl)-7H-purin-2-yl]amino]benzenesulfonamide
• InChI: InChI=1S/C23H18N6O2S/c24-32(30,31)19-11-9-18(10-12-19)27-23-28-20(21-22(29-23)26-14-25-21)17-8-4-7-16(13-17)15-5-2-1-3-6-15/h1-14H,(H2,24,30,31)(H2,25,26,27,28,29)
• InChIKey: FUGRWXRQJGJIER-UHFFFAOYSA-N
• SMILES: C1=CC=C(C=C1)C2=CC(=CC=C2)C3=C4C(=NC(=N3)NC5=CC=C(C=C5)S(=O)(=O)N)N=CN4

CDK2-IN-4（Cat No.:I019049）is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), an important regulator of the cell cycle, particularly in the transition from the G1 to S phase. By specifically inhibiting CDK2, this compound disrupts the phosphorylation of key substrates involved in cell cycle progression, leading to cell cycle arrest and potential apoptosis in cancer cells. Its selectivity makes it a promising candidate for targeted cancer therapies, especially in tumors that exhibit aberrant CDK2 activity. Preclinical studies suggest CDK2-IN-4 may effectively overcome therapeutic resistance in certain malignancies.

Reference

[1]. Coxon CR, et al. Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. J Med Chem. 2017 Mar 9;60(5):1746-1767.